The medtech start-up said its blood test for early detection of ovarian cancer could ‘potentially dramatically increase patient survival’.
GenoMe Diagnostics, a Belfast medtech start-up, has raised £300,000 in a seed round for its ovarian cancer diagnostics technology.
The start-up, a spin-out from Queen’s University Belfast that was founded last year, is developing a novel blood test for the earlier diagnosis of ovarian cancer.
The round of funding comes from QUBIS, a department of Queen’s University that is responsible for investing in university spin-outs and helping them commercialise, Deepbridge Capital, and Co-Fund NI, government-backed fund for investing in Northern Irish start-ups.
GenoMe has its roots at the Patrick G Johnston Centre for Cancer Research at Queen’s University and is based on research by Dr Paul Mullan, Dr James Beirne and Dr Laura Feeney. The company is joined by Dr Shannon Beattie, who is chief operating officer.
“Our work benefits women who are at risk of developing ovarian cancer, or who present with possible symptoms. Early diagnosis can ultimately save lives, as well as reduce cost pressures for healthcare providers,” Beattie said.
“We also aim to benefit clinical trial providers and drug developers, by developing accurate and cost-effective companion diagnostics, to better stratify patients and increase their chance of response to novel therapies.”
Mullan said that ovarian cancer is often detected in the later stages and earlier diagnosis – especially by catching tumours when they are small and less likely to be resistant to chemotherapy – could “potentially dramatically increase patient survival”.
GenoMe is the latest university spin-out that QUBIS has invested in this year, building on research conducted at the university that has the potential for commercialisation. Earlier this month, it backed VascVersa, which is developing a treatment for damaged blood vessels, and FjordStrong, which is building underwater surveying systems.
“GenoME Diagnostics builds on 10 years of research at Queen’s and the team has made great progress on their commercialisation journey,” Anne Dornan, enterprise network manager at QUIBIS, said.
“GenoME has the potential to improve outcomes for women at risk of developing ovarian cancer across the globe, QUBIS along with the other funders involved, look forward to supporting the company through its early-stage development, and wish the team every success for the future.”
The start-up previously won the All Ireland Best New Start Company in the Intertrade Ireland Seedcorn competition in 2020.
In a countersuit released last week, Musk put his side of the argument. According to him: Twitter misled investors; it breached the agreement by failing to provide enough information on spam accounts; another breach occurred when Twitter failed to consult with him on business moves such as firing senior employees; and its misstatement of user numbers constitutes a material adverse effect, which substantially alters Twitter’s value and therefore invalidates the deal agreement.
“Instead, they contain numerous, material misrepresentations or omissions that distort Twitter’s value and caused the Musk parties to agree to acquire the company at an inflated price. Twitter’s complaint, filled with personal attacks against Musk and gaudy rhetoric more directed at a media audience than this court, is nothing more than an attempt to distract from these misrepresentations,” said the lawsuit.
Strong words, but Musk will need strong evidence as well to convince the judge.
Musk’s core argument is about user numbers
From the moment the deal started to go sour, the focus was on the veracity of Twitter’s numbers. It is at the centre of Musk’s countersuit as well. He argues that the number of monetisable daily average users (mDAUs) – authentic, active accounts that can see adverts (hence monetisable) – is falsely inflated by Twitter miscounting the number of false and spam accounts on the platform. As well as being a threat to the ad income on which Twitter depends, Musk said his plan to introduce a subscription service for Twitter would be affected because there would be fewer customers to target than first thought.
Twitter has consistently stated that it estimates the number of false or spam accounts on the platform to be less than 5% of its mDAUs base, which stands at just under 238 million currently.
The suit says that Musk became alarmed about how Twitter accounts for its mDAUs when, three days after signing the deal agreement, it admitted it had overstated its mDAU total for three years, by between 1.4 million and 1.9 million users per quarter. Twitter denies that the user change was a “restatement” (it describes the alteration as “updated values”) but admits it did not give the information to Musk prior to the deal being signed on 25 April.
Musk is not happy with Twitter’s verification processes
After agreeing to buy the business with minimal due diligence, the suit says Musk was “astonished” to learn about how “meagre” Twitter’s processes for identifying spam accounts were. It said 100 accounts a day were sampled by human reviewers in order to come up with the less-than-5% figure. Twitter’s CEO and chief financial officer were unable to explain how these accounts were selected to be a representative sample.
“Musk realised that, at best, Twitter’s reliance on and touting of its process was reckless; at worst, it was intentionally misleading,” says the suit.
Twitter argues that it uses a much more layered process for weeding out dodgy accounts, including using automated systems. It also pointed to the detailed explanations of how it polices spam accounts, which had been given to Musk, the press, the Securities and Exchange Commission and the public via a Twitter thread by CEO Parag Agrawal. In the most notorious episode of this takeover saga, Musk replied to the latter with a poo emoji.
But according to the countersuit at least Agrawal and Musk agreed on one thing. The document states that on 8 April Musk sent the CEO an example of a spam tweet saying: “I am so sick of stuff like this.” Agrawal replied, acknowledging “[w]e should be catching this.”
Citing “preliminary expert estimates”, the countersuit claims that in early July one-third of visible accounts may have been false or spam. This means that the true proportion of spam accounts among Twitter’s user base is at least 10%.
It says users that see zero or almost no ads account for almost all the growth in monetisable daily users. The majority of ads are served to less than 16 million users, the suit claims.
Twitter says that although not every user sees ads on a given day, in the first quarter “significantly more than” 229 million accounts contributed to Twitter’s average quarterly user number.
Regarding the 10% number, Twitter says it was based on a publicly available web tool, botometer, that has designated Musk’s own account as a likely bot.
Twitter made decisions without consulting Musk
One of the clauses in the merger agreement states Musk must be told when Twitter is deviating from its obligation to conduct its business in the “ordinary course”. In the countersuit, Musk claims that Twitter has made several “significant” changes – including firing two executives, starting a hiring freeze and initiating a legal clash with the Indian government – that occurred without his consent.
Twitter’s response is that axing employees or acting to protect users’ rights in foreign jurisdictions are part of the day-to-day business of running a company.
Information was not forthcoming
Musk is also claiming that Twitter failed to provide him with all the data and information that he requested “for any reasonable business purpose related to the consummation of the transaction”. The suit says Musk was sent reams of “stale data” that didn’t answer his questions.
It says, pointedly, that Twitter was happy to send data such as “a copy of its agreement with the Golden State Warriors for courtside basketball tickets and VIP parking”.
After more back-and-forth arguments over increasingly detailed information requests, the suit claims “the only conclusion the Musk parties could draw from Twitter’s obfuscation and delay was that Twitter knew that it had something to hide”.
The hyperscalers and public cloud providers are barreling ahead, unfazed by a rapidly deteriorating economic outlook, according to a recent Dell’Oro Group report.
In fact, these internet behemoths stand to benefit from the current market conditions in more ways than one, analyst Baron Fung told The Register.
As chipmakers like Intel, Nvidia, Micron, and others face increased pricing pressure across their lineups due to declining demand, hyperscalers are well-positioned to take advantage of this and add more capacity on the cheap, he explained.
“Looking at the recent Q2 earnings, it was really pretty impressive from a growth standpoint,” Fung said of the cloud providers.
Amazon and Azure in particular saw robust revenue gains in their most recent quarters. AWS saw revenues climb 36 percent from the prior year, while Microsoft reported its cloud biz saw year-over-year growth of 40 percent. However, things weren’t as peachy for Google, which saw a otherwise strong quarter for cloud revenue tempered by a $858 million loss in income.
Worsening macroeconomic factors may end up helping cloud providers as enterprises look for alternatives to capex-heavy server refreshes. We saw this phenomenon once before – in the early days of the pandemic.
These factors, combined with a wave of enabling technology – next-generation CPUs, GPUs, smartNICs, and CXL-enabled components to name a handful – will further accelerate hyperscaler spending, which is expected to grow 13 percent over the next five years, Fung said.
So it’s no surprise many chipmakers are optimistic about their cloud and datacenter-related revenues over the next few quarters, despite a slump in PC and gaming demand.
The analyst firm expects next-generation CPU platforms from the likes of Intel, AMD, and Ampere will be among the strongest drivers of hyperscale spending in the near term.
Intel and AMD are expected to launch their next-generation server processors later this year. Both of these chips pack a bevy of new features, including DDR5, and PCIe 5.0, in addition to having substantially higher core counts compared to the previous generation.
These chips are also among the first to support the CXL interconnect standard, “which will enable a new kind of paradigm in the datacenter,” according to Fung.
In its first iteration, the technology will allow systems builders to pack larger quantities of memory into servers than there are DIMM slots, using CXL memory-expansion modules. And in the years to come, the technology has provisions for tiered memory, memory pooling, and disaggregated compute architectures.
The operational and resource efficiencies enabled by the tech may eventually trickle down to customers in the form of lower prices, Fung added.
But it won’t just be the x86 stalwarts leading the charge in the datacenter. Fung also expects Arm chipmakers, like Ampere, to continue gaining traction in the hyperscale arena. Here, the chipmaker’s Altra and Altra Max processors have already attracted several high-profile customers including Microsoft Azure, Google, Cloudflare, and Oracle – to name just a few.
Finally, Dell’Oro predicts hyperscalers will drive edge infrastructure deployments – a market that Intel currently dominates – to 8 percent of the total datacenter infrastructure market by 2026. ®
The Irish-based study lead said food scientists, medical scientists and pharma companies must work together to produce functional foods to treat chronic conditions.
A team of researchers based at the Bernal Institute in University of Limerick (UL) have developed a new guide to designing functional foods to treat various chronic conditions.
Functional foods are foods that provide nutrition and act in a way that positively affects the body, similar to medicine.
According to the research, food has the potential to help in the treatment of heart diseases such as atherosclerosis.
“The capacity for our food to do more than provide us with nutrition is huge and relatively unexplored,” said study lead Daniel Granato, professor in food science and health at UL.
“Cardiovascular diseases are a main cause of death but they can be prevented. By bringing food scientists, medical scientists and pharma companies together we can employ the same methods used in producing medicinal drugs and produce foods that might mitigate health conditions,” Granato added.
The study has been published in Trends in Food Science & Technology, an academic journal. The UL researchers were joined on the project by academics from the Federal University of Alfenas and Universidade Federal de Minas Gerais in Brazil.
Granato and his team proposed an accurate computational approach to designing functional foods by predicting their bioactivity. This allowed the researchers to map how different food components benefit the body.
The study also drew attention to the potential of functional foods to treat illnesses and lessen the burden on the world’s health services. Functional foods are not too available on the market, despite their potential to help prevent conditions such as type-2 diabetes and glucose intolerance. These are both major contributors to heart disease.
Food science, cardiovascular disease therapy and computer modelling should be linked to produce functional foods that can mitigate atherosclerosis, according to Granato. He urged food and pharma companies to take note.
“This is critical to achieve United Nations Sustainable Development Goals in good health and wellbeing, as well as ensuring healthy lives and promoting wellbeing for all at all ages, by optimising discovery of bioactive compound sources, and reducing time to market for new functional foods,” he said.
Granato’s co-author and senior lecturer in the UL Department of Biological Sciences, Dr Andreas Grabrucker, said this approach could go far beyond heart disease.
“It will be the basis of a new research project at UL that aims to identify functional foods that lower the risk for neurodegenerative disorders such as Alzheimer’s disease,” he claimed.
10 things you need to know direct to your inbox every weekday. Sign up for the Daily Brief, Silicon Republic’s digest of essential sci-tech news.